Biovica Q1 Interim report May 2025 – July 2025 - Biovica International AB
11.9 julkaistu osavuosi
Tappio pieneni pikkaisen, mutta ei vielä merkittävää parannusta. Lisää myyntiä vaaditaan, että paastään luvattuun 2026 loppuvuoden voitolliseen tulokseen. Mielenkiinnolla seurailen mitä tapahtuu.
| SEK 000s | Q1 25/26 | Q1 24/25 | May-April 24/25 |
|---|---|---|---|
| Net sales | 2,596 | 1,714 | 8,619 |
| Operating profit (loss) | -19,334 | -23,562 | -85,839 |
| Earnings per share, after dilution | -0.18 | -0.27 | -0.95 |
| Number of shares at the end of the period | 97,786,384 | 84,055,560 | 92,569,248 |
| Cash and cash equivalents at the end of the period | 16,305 | 65,209 | 24,415 |
| Cash flow from operating activities | -17,196 | -29,044 | -85,367 |
| Average number of employees | 25 | 27 | 26 |
Significant events during the first quarter
-
Biovica is now collaborating with Tempus to expand the commercial reach of DiviTum TKa
-
Biovica signed a significant Master Service Agreement (MSA) and first work order under that agreement for SEK 4 million
-
New data on DiviTum TKa for use in three areas of cancer presented at ASCO
-
Biovica secured three new assignments worth SEK 2.5 million in the Pharma Services part of the business
-
Biovica announced financial targets reflecting its important partnership and commercial success
-
Biovica resolved on a fully guaranteed rights issue of approximately SEK 80 million at SEK 0.63 per share
-
Biovica signed an agreement with its fifth Tier 1 biopharma company in the USA
Significant events after the end of the period